Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates

Although unprecedented efforts aiming to stop the COVID-19 pandemic have been made over the past two years, SARSCoV-2 virus still continues to cause intolerable health and economical losses. Vaccines are considered the most effective way to prevent infectious diseases, which has been reaffirmed for...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Amir I. Tukhvatulin, Ilya V. Gordeychuk, Inna V. Dolzhikova, Alina S. Dzharullaeva, Marina E. Krasina, Ekaterina O. Bayurova, Daria M. Grousova, Anna V. Kovyrshina, Alla S. Kondrashova, Daria V. Avdoshina, Stanislav A. Gulyaev, Tatiana V. Gulyaeva, Andrey V. Moroz, Viktoria V. Illarionova, Ilya D. Zorkov, Anna A. Iliukhina, Artem Y. Shelkov, Andrei G. Botikov, Alina S. Erokhova, Dmitry V. Shcheblyakov, Ilias B. Esmagambetov, Olga V. Zubkova, Elisaveta A. Tokarskaya, Daria M. Savina, Yulia R. Vereveyko, Anastasiya S. Ungur, Boris S. Naroditsky, Aydar A. Ishmukhametov, Denis Y. Logunov, Alexander L. Gintsburg
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2022-12-01
coleção:	Emerging Microbes and Infections
Assuntos:	Sputnik V Gam-COVID-Vac intranasal vaccine SARS-CoV-2 COVID-19
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/22221751.2022.2119169
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!